A Single 48 mg Sucralose Sip Unbalances Monocyte Subpopulations and Stimulates Insulin Secretion in Healthy Young Adults

Figure 3

Cell surface expression of CD11c and CD206 in classical, intermediate, and nonclassical monocytes of healthy young adults that received sucralose or placebo at the beginning and at the end of an oral glucose tolerance test. (a) As expected, CD11c expression showed no differences between placebo and sucralose groups at the beginning (-15 min) of the oral glucose tolerance test (OGTT). At 180 min, CD11c expression significantly decreased in intermediate monocytes (IM) and nonclassical monocytes (NCM) of subjects that received 48 mg sucralose as compared to placebo controls. When comparing -15 and 180 min, classical monocytes (CM), IM, and NCM showed decreased CD11c expression in volunteers receiving sucralose. (b) CD206 expression showed no differences in subjects receiving placebo or sucralose at the beginning of the OGTT (-15 min). At 180 min, CD206 expression significantly decreased in the NCM subpopulation of subjects that received sucralose as compared to placebo controls. The placebo group is shown in open bars, whereas the sucralose group can be seen in closed bars. Monocytes were gated on a CD14⁺CD16⁺ dot plot to identify CD14⁺⁺CD16^- classical monocytes, CD14⁺⁺CD16⁺ intermediate monocytes, and CD14⁺CD16⁺ nonclassical monocytes and then measure the mean fluorescence intensity (MFI) of CD11c and CD206 on each monocyte subset. Data are expressed as deviation. Significant differences between subjects receiving placebo or sucralose were estimated by performing two-tailed, 2-way ANOVA followed by the Bonferroni multiple comparisons test. Significant differences are indicated by asterisks. Differences were considered significant when .

(a)

(b)